BioNTech WKN: A2PSR2 ISIN: US09075V1026 Forum: Aktien Thema: Hauptdiskussion

Moderna (MRNA) Faces Critical Phase III Melanoma Trial Data Release Author's Avatar GuruFocus News 09/23/2026 09:50 On September 23, 2026, UBS maintained a "Neutral" rating on Moderna MRNA ahead of the critical Phase III trial results for its melanoma treatment, setting a target price of $150. The market is keenly awaiting these results, which will be presented at the European Society for Medical Oncology conference, focusing on the key metric of disease-free survival. The anticipation surrounding Moderna's Phase III trial results is palpable, as the outcomes could significantly impact the company’s valuation and stock price. UBS has highlighted that the market is expecting a hazard ratio of 0.65 or lower, which would indicate a 35% reduction in the risk of disease recurrence or death compared to the control group. A favorable outcome could potentially boost Moderna's stock by 10% to 20%, while an unfavorable result could lead to a negative market reaction. Moderna Inc. is a commercial-stage biotechnology company that develops messenger RNA (mRNA) therapeutics and vaccines. With a market capitalization of approximately $72.88 billion, the company operates within the healthcare sector, specifically in the biotechnology industry. Its notable products include the COVID-19 vaccine, Spikevax, and a pipeline that spans various diseases, including oncology and rare genetic disorders. Is MRNA Overvalued on a Price-to-Sales Basis? Currently, Moderna's Price-to-Sales (P/S) ratio is significantly elevated compared to its historical median of approximately 8.5x, indicating that the stock is trading at a premium relative to its past performance and industry standards. Given that Moderna is currently unprofitable and cash-flow-negative, the Price-to-Earnings (P/E) ratio is not a meaningful metric for valuation. The market appears to be pricing in high expectations for future growth based on the upcoming trial results. As a directional warning, the GF Value™ for Moderna is calculated at $24.05, indicating that the stock is currently overvalued by approximately 659.1%. For further details on GF Value™, visit GF Value™.

Das ist nicht von Dauer, und das weiß jeder.

Moderna.

Average Target Price 112.72 Number Of Ratings 25

Interessiert die Börse null und das ist Fakt

Und BioNTech ist unterbewertet. Deutlich.

Ich behaupte, dass die Interessen von Moderna/BioNTech bestimmen, wie die Diskussion hier geführt wird. Wollen Sie das bestreiten?

Schreibt einer, der gerade mal ein paar Monate dabei ist 😉

Moderna ist völlig überbewertet. Voilà. Das ist die Wahrheit.

Das wäre wirklich naiv.

Ich behaupte, dass die Interessen von Moderna/BioNTech bestimmen, wie die Diskussion hier geführt wird. Wollen Sie das bestreiten?

Da laufen doch die gleichen wie hier rum… das hier ist nen Börsenforum und nicht das New Yorker/Frankfurter Börsenparkett, was hier im Forum passiert hat genau null mit dem zu tun was mit dem Kurs passiert

Und was erklärt das deiner Meinung nach?

Es ist sehr interessant, einen Blick auf das Moderna-Forum und die dort anwesenden Befürworter zu werfen. Das erklärt so einiges.

Canaccord Genuity Reaffirms Their Buy Rating on BioNTech SE (BNTX) TipRanks Auto-Generated Intelligence Newsdesk Sep 23, 2026, 11:15 AM Canaccord Genuity analyst John Newman maintained a Buy rating on BioNTech SE today and set a price target of $136.00. According to TipRanks, Newman is a 3-star analyst with an average return of 1.0% and a 43.66% success rate. Newman covers the Healthcare sector, focusing on stocks such as Tyra Bioscience, Adicet Bio, and Tango Therapeutics. https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-biontech-se-bntx-blurbs-news-2?mod=mw_quote_news

da kennst du dich mit aus, zi p f el Gesicht 168